Chat with us
Medical Science 2025 Paper II 50 marks Elaborate

Paper II — Q3

(a) (i) Elaborate the indications for initiating antiviral therapy in a patient with chronic hepatitis B. (ii) Write the…

(a)
(i)

Elaborate the indications for initiating antiviral therapy in a patient with chronic hepatitis B.

(ii)

Write the first-line antivirus treatment regimen for the management of chronic hepatitis B along with the recommended monitoring strategy during therapy. 10+15=25

(b)

Write the risk factors for respiratory distress syndrome (RDS) in newborn. What is the differential diagnosis of RDS? How will you manage respiratory distress syndrome in newborn? 5+5+5=15

(c)
(i)

A 28-year-old female with a long history of psoriasis develops symmetrical, flexural and grouped pustules with high grade fever and severe constitutional symptoms in the third trimester. What is your diagnosis?

(ii)

How do you manage the condition?

(iii)

What are the complications? 3+4+3=10

हिंदी में प्रश्न पढ़ें
(a)
(i)

चिरकारी यकृतशोथ B के रोगी में प्रतिवाइरसी चिकित्सा आरंभ करने के संकेतों को विस्तार से बताइए।

(ii)

चिरकारी यकृतशोथ B के प्रबंधन के लिए प्रथम पंक्ति का प्रतिवाइरसी चिकित्सा विधान तथा चिकित्सा अवधि में अनुशंसित निगरानी रणनीति लिखिए। 10+15=25

(b)

नवजात में श्वसन कष्ट संलक्षण (आर. डी. एस.) के जोखिमकारक तत्व लिखिए। श्वसन कष्ट संलक्षण का विभेदक निदान क्या है? नवजात में श्वसन कष्ट संलक्षण का प्रबंधन कैसे किया जाता है? 5+5+5=15

(c)
(i)

एक 28-वर्षीय महिला, जिसे सोरियासिस होने की लंबी हिस्ट्री है, उसे सममित, बंक में तथा समूहों में पुस्ट्यूलोटिकाएं पन्न आई हैं जिसके साथ उच्च श्रेणी (ग्रेड) का ज्वर है तथा प्रचंड शारीरिक (कांस्टिट्यूशनल) लक्षण हैं। यह महिला तीसरे त्रैमास में है। निदान क्या है?

(ii)

इस रुग्णता का प्रबंधन कैसे करेंगे?

(iii)

इसकी क्या-क्या जटिलताएं हैं? 3+4+3=10

Q3 of the 2025 UPSC Mains Medical Science Paper II, as printed
The question as printed in the 2025 Medical Science paper
Evaluate your answer to this question → See all 2025 Medical Science questions

Model answer

Written by UPSC Answer Check against this question's marking rubric, to the expected length. UPSC does not publish answers for Mains — this is one way to score well, not an official key.

Indications for Antiviral Therapy in Chronic Hepatitis B

Antiviral therapy in Chronic Hepatitis B (CHB) aims to achieve sustained suppression of HBV replication, prevent progression to cirrhosis, decompensation, and hepatocellular carcinoma (HCC). Treatment is indicated in:

  1. Immune-active HBeAg-positive CHB: Serum HBV DNA >20,000 IU/mL with elevated serum alanine aminotransferase (ALT >2× upper limit of normal [ULN]).
  2. Immune-active HBeAg-negative CHB: Serum HBV DNA >2,000 IU/mL with ALT >2× ULN.
  3. Cirrhosis (compensated or decompensated): Detectable serum HBV DNA at any level, regardless of ALT value.
  4. Non-invasive markers of liver injury: Significant fibrosis (≥F2 by transient elastography/FibroScan or APRI score >1.5) or moderate-to-severe necroinflammation on biopsy, even if ALT is normal or minimally elevated.
  5. High-risk demographics: Patients older than 30 years with persistent replication (HBV DNA >2,000 IU/mL) and a family history of cirrhosis or HCC, or those planned for systemic immunosuppression/chemotherapy.

First-Line Antiviral Regimens and Monitoring Strategy

First-line treatment utilizes high-potency oral nucleos(t)ide analogues with a high barrier to resistance:

  • Tenofovir Disoproxil Fumarate (TDF): 300 mg once daily orally (safe in pregnancy and treatment-experienced cases).
  • Entecavir (ETV): 0.5 mg once daily orally in treatment-naïve patients, or 1.0 mg once daily in lamivudine-experienced patients.

Monitoring Strategy:

  • Virologic and biochemical efficacy: ALT and serum HBV DNA quantified every 3 to 6 months until virological suppression (<20 IU/mL), then every 6 months.
  • Serology: HBeAg and anti-HBe checked every 6–12 months in HBeAg-positive patients. Quantitative HBsAg checked annually to detect HBsAg loss/seroconversion.
  • Drug safety: Serum creatinine, estimated GFR, and serum phosphate assessed at baseline and every 3–6 months for TDF nephrotoxicity and bone loss.
  • Resistance: Genotypic resistance testing is mandated if virologic breakthrough (HBV DNA rebound >1 log10 above nadir) occurs during compliant therapy.

Respiratory Distress Syndrome (RDS) in Newborns

Risk Factors: Primary driver is surfactant deficiency due to prematurity (<34 weeks). Other factors include maternal diabetes mellitus, elective caesarean delivery without prior labour or antenatal corticosteroid coverage, male sex, perinatal asphyxia, and being the second-born twin.

Differential Diagnosis: Transient Tachypnoea of the Newborn (TTN), neonatal sepsis/congenital pneumonia, Meconium Aspiration Syndrome (MAS), Congenital Heart Disease (such as critical cyanotic CHD or large patent ductus arteriosus), and pulmonary haemorrhage.

Management:

  • Resuscitation and Oxygenation: Early application of continuous positive airway pressure (CPAP, 5–6 cm H2O) in the delivery room via nasal prongs to maintain functional residual capacity.
  • Surfactant Replacement Therapy: Natural exogenous surfactant (such as Poractant alfa 100–200 mg/kg) administered via catheter (LISA/MIST technique) or endotracheal tube if oxygen requirement rises (FiO2 >0.30 on CPAP).
  • Mechanical Ventilation: Synchronised intermittent mandatory ventilation or high-frequency oscillatory ventilation indicated for severe respiratory acidosis (pH <7.20, PaCO2 >60 mmHg) or refractory hypoxaemia.
  • Supportive Care: Strict thermoregulation, judicious intravenous fluid management, empirical intravenous antibiotics (ampicillin and gentamicin) pending blood culture clearance, and blood pressure maintenance.

Clinical Vignette: Pustular Eruption in Pregnancy

Diagnosis: Impetigo Herpetiformis (a severe form of generalised pustular psoriasis occurring during pregnancy, typically triggered by third-trimester hormonal shifts and associated with hypocalcaemia). Differentials include acute generalised pustular psoriasis (AGPP) and acute generalised exanthematous pustulosis (AGEP).

Management:

  • Multidisciplinary Care: Joint management between dermatology, obstetrics, and neonatology in an intensive care setting.
  • Pharmacotherapy: Systemic corticosteroids are first-line (Oral Prednisolone 0.5–1.0 mg/kg/day). In refractory cases, oral Cyclosporine (3–5 mg/kg/day) acts as a rapid, steroid-sparing agent safe in late pregnancy.
  • Supportive Therapy: Fluid resuscitation, correction of electrolyte derangements, and aggressive parenteral calcium repletion.
  • Obstetric Plan: Fetal surveillance via cardiotocography and Doppler. Prompt induction of labour or delivery if near term or in the presence of fetal compromise, which typically leads to rapid maternal resolution.

Complications:

  • Maternal: Severe hypocalcaemia leading to tetany, secondary bacterial sepsis, high-output cardiac failure, and placental insufficiency leading to premature labour.
  • Fetal: Intrauterine growth restriction (IUGR), preterm birth, intrauterine fetal demise/stillbirth, and neonatal sepsis. There is a high risk of recurrence in subsequent pregnancies.

A high index of suspicion, timely pathogen-directed or organ-supportive interventions, and multidisciplinary monitoring remain decisive in preventing maternal-fetal and systemic morbidity across these acute and chronic conditions.

What "Elaborate" is asking you to do

Give the full detailed account the question has compressed into a line — every dimension of it, with specifics. Elaborate rewards completeness and detail rather than clarification or argument: the examiner is checking whether you can fill out a topic without being told what its parts are.

Structure that answers it

State the proposition → first dimension in detail → second dimension in detail → the part the statement leaves implicit → the consolidated picture

Where marks are lost

Repeating the statement at greater length instead of adding substance. Elaborate also punishes narrowness: omitting a whole dimension costs more here than anywhere else in this family.

All UPSC directive words, compared →

How this answer will be evaluated

Approach

Framework: Clinical Sequence (Definition > Aetiology > Features > Investigation > Management). (a(i)) explain: definition/context > points in order > small example > short close | (a(ii)) describe: define > structure or process in order > labelled diagram > significance | (b) describe: define > structure or process in order > labelled diagram > significance | (c(i)) define: precise definition > the distinguishing feature > one example | (c(ii)) suggest: the problem in one line > implementable measures > who acts > conclusion | (c(iii)) enumerate: list the items in order > one line each > no commentary Full marks: Precise clinical criteria, correct first-line drugs, and safe management in pregnancy.

Key points expected

  • HBeAg positive with elevated ALT
  • HBeAg negative with elevated ALT
  • Presence of cirrhosis (regardless of ALT)
  • Extrahepatic manifestations (e.g., glomerulonephritis)
  • Identify Entecavir and Tenofovir as first-line agents
  • Monitoring of HBV DNA levels
  • Monitoring of ALT/AST levels
  • Monitoring for HCC (ultrasound/alpha-fetoprotein)

Evaluation rubric

Each sub-part is marked on its own, against the marks and word limit printed on the paper.

  1. (a(i)) List and justify indications for starting antiviral therapy in chronic Hep B. 10 marks

    explain— definition/context → points in order → small example → short close

    Must cover

    • HBeAg positive with elevated ALT
    • HBeAg negative with elevated ALT
    • Presence of cirrhosis (regardless of ALT)
    • Extrahepatic manifestations (e.g., glomerulonephritis)

    Loses marks

    • Listing symptoms without linking to treatment criteria
    • Omitting cirrhosis as an indication

    Earns more

    • Mention of HBV DNA threshold (e.g., >20,000 IU/mL)
    • Family history of HCC
    • Age >40 years with elevated DNA

    Extra mark

    • Reference to AASLD or EASL guidelines
  2. (a(ii)) Detail first-line antiviral regimens and the monitoring protocol during therapy. 15 marks

    describe— define → structure or process in order → labelled diagram → significance

    Must cover

    • Identify Entecavir and Tenofovir as first-line agents
    • Monitoring of HBV DNA levels
    • Monitoring of ALT/AST levels
    • Monitoring for HCC (ultrasound/alpha-fetoprotein)

    Loses marks

    • Listing drugs without monitoring strategy
    • Omitting HCC surveillance in monitoring

    Earns more

    • Mention of treatment duration (lifelong vs. finite)
    • Monitoring for drug resistance (HBeAg seroconversion)

    Extra mark

    • Mention of specific drug dosages
  3. (b) Outline risk factors, differential diagnosis, and management of neonatal RDS. 15 marks

    describe— define → structure or process in order → labelled diagram → significance

    Must cover

    • Risk factors: prematurity, maternal diabetes, C-section
    • Differential: TTN, pneumonia, meconium aspiration
    • Management: CPAP, surfactant therapy, oxygen
    • Supportive care: thermoregulation, fluids

    Loses marks

    • Confusing RDS with TTN in differential
    • Management without priority (e.g., surfactant before CPAP)

    Earns more

    • Mention of antenatal steroids for prevention
    • Specifics on surfactant administration (INSURE technique)

    Extra mark

    • Mention of specific oxygen saturation targets
  4. (c(i)) Provide the specific diagnosis for the clinical vignette. 3 marks

    define— precise definition → the distinguishing feature → one example

    Must cover

    • Diagnosis: Generalized Pustular Psoriasis (von Zumbusch)
    • Context: Triggered by pregnancy (3rd trimester)

    Loses marks

    • Diagnosing as simple plaque psoriasis
    • Diagnosing as impetigo or infection

    Earns more

    • Mention of 'acute' onset

    Extra mark

    • Mention of 'von Zumbusch' eponym
  5. (c(ii)) Outline the management plan for the condition in pregnancy. 4 marks

    suggest— the problem in one line → implementable measures → who acts → conclusion

    Must cover

    • Supportive care (fluids, electrolytes)
    • Systemic corticosteroids (if severe)
    • Cyclosporine (if refractory)
    • Avoidance of contraindicated drugs (methotrexate, retinoids)

    Loses marks

    • Suggesting methotrexate or isotretinoin
    • Ignoring maternal safety in pregnancy

    Earns more

    • Mention of delivery timing (if maternal condition worsens)

    Extra mark

    • Mention of specific steroid dosages
  6. (c(iii)) List the potential complications of the condition. 3 marks

    enumerate— list the items in order → one line each → no commentary

    Must cover

    • Maternal: Sepsis, electrolyte imbalance, heart failure
    • Fetal: Preterm labor, fetal distress

    Loses marks

    • Listing complications of simple psoriasis only
    • Omitting fetal complications

    Earns more

    • Mention of renal failure

    Extra mark

    • Mention of specific electrolyte (hypocalcemia)

Practice this exact question

Write your answer and it is marked point by point against the model answer above — what you covered, what you missed, what you got wrong.

Evaluate my answer →

More from Medical Science 2025 Paper II